Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)

被引：33

作者：

Zhang, Lei ^{[1
]}

Lebwohl, David ^{[1
]}

Masson, Eric ^{[1
]}

Laird, Glen ^{[1
]}

Cooper, Michael R. ^{[2
]}

Prince, H. Miles ^{[3
,4
]}

机构：

[1] Novartis Pharmaceut Corp, E Hanover, NJ USA

[2] Novartis Inst Biomed Res, Cambridge, MA USA

[3] Univ Melbourne, Melbourne, Vic, Australia

[4] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 02期

关键词：

D O I：

10.1200/JCO.2007.14.7249

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：332 / 333

页数：2

共 12 条

[1] Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].

Duvic, Madeleine ;

Talpur, Rakshandra ;

Ni, Xiao ;

Zhang, Chunlei ;

Hazarika, Parul ;

Kelly, Cecilia ;

Chiao, Judy H. ;

Reilly, John F. ;

Ricker, Justin L. ;

Richon, Victoria M. ;

Frankel, Stanley R. .

BLOOD, 2007, 109 (01) :31-39

[2] A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies [J].

Giles, Francis ;

Fischer, Thomas ;

Cortes, Jorge ;

Garcia-Manero, Guillermo ;

Beck, Joachim ;

Ravandi, Farhad ;

Masson, Eric ;

Rae, Patricia ;

Laird, Glen ;

Sharma, Sunil ;

Kantarjian, Hagop ;

Dugan, Margaret ;

Albitar, Maher ;

Bhalla, Kapil .

CLINICAL CANCER RESEARCH, 2006, 12 (15) :4628-4635

[3] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer [J].

Kelly, WK ;

O'Connor, OA ;

Krug, LM ;

Chiao, JH ;

Heaney, M ;

Curley, T ;

MacGregore-Cortelli, B ;

Tong, W ;

Secrist, JP ;

Schwartz, L ;

Richardson, S ;

Chu, E ;

Olgac, S ;

Marks, PA ;

Scher, H ;

Richon, VM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3923-3931

[4]

Kelly WK, 2003, CLIN CANCER RES, V9, P3578

[5] Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies [J].

O'Connor, OA ;

Heaney, ML ;

Schwartz, L ;

Richardson, S ;

Willim, R ;

MacGregor-Cortelli, B ;

Curly, T ;

Moskowitz, C ;

Portlock, C ;

Horwitz, S ;

Zelenetz, AD ;

Frankel, S ;

Richon, V ;

Marks, P ;

Kelly, WK .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :166-173

[6] Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma [J].

Olsen, Elise A. ;

Kim, Youn H. ;

Kuzel, Timothy M. ;

Pacheco, Theresa R. ;

Foss, Francine M. ;

Parker, Sareeta ;

Frankel, Stanley R. ;

Chen, Cong ;

Ricker, Justin L. ;

Arduino, Jean Marie ;

Duvic, Madeleine .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) :3109-3115

[7] Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma [J].

Piekarz, Richard L. ;

Frye, A. Robin ;

Wright, John J. ;

Steinberg, Seth M. ;

Liewehr, David J. ;

Rosing, Douglas R. ;

Sachdev, Vandana ;

Fojo, Tito ;

Bates, Susan E. .

CLINICAL CANCER RESEARCH, 2006, 12 (12) :3762-3773

[8]

PRINCE HM, 2007, ECCO SEP 23 27 BARC

[9]

ROWINSKY EK, 2005, J CLIN ONCOL, V23, pS16

[10] Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors [J].

Shah, Manisha H. ;

Binkley, Philip ;

Chan, Kenneth ;

Xiao, Jim ;

Arbogast, Daria ;

Collamore, Minden ;

Farra, Yasser ;

Young, Donn ;

Grever, Michael .

CLINICAL CANCER RESEARCH, 2006, 12 (13) :3997-4003

← 1 2 →